DGIdb - COMT Gene Record

COMT 1312 Druggable Genome

Alternate Names:

1312
CATECHOL-O-METHYLTRANSFERASE
COMT
HEL-S-98n
116790
2228
ENSG00000093010
OTTHUMG00000150529
P21964
COMT_HUMAN
PA117
Catechol O-methyltransferase
CATECHOL-O-METHYL-TRANSFERASE
T76904

Gene Info:

Target Class	Enzymes
Target Subclass	EC:2.1.1.6
Target Main Class	Enzymes
Target Subclass	2.1.1.6
Gene Biotype	PROTEIN_CODING

(3 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME

Publications:

Benedetti F et al., 2010, Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine., Eur Psychiatry
Stocchi et al., 2006, Utility of tolcapone in fluctuating Parkinson's disease., Clin Interv Aging
Truong, 2009, Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease., Clin Interv Aging
Ries et al., 2010, Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study., Clin Neuropharmacol
Kaakkola, 2000, Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease., Drugs
Tai et al., 2002, Catechol-O-methyltransferase and Parkinson's disease., Acta Med. Okayama
Keating et al., 2005, Tolcapone: a review of its use in the management of Parkinson's disease., CNS Drugs
Ruottinen et al., 1998, COMT inhibition in the treatment of Parkinson's disease., J. Neurol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Apud et al., 2007, Tolcapone improves cognition and cortical information processing in normal human subjects., Neuropsychopharmacology
Forsberg et al., 2003, Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat., J. Pharmacol. Exp. Ther.
Guay, 1999, Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease., Pharmacotherapy
Myer NM et al., 2018, Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD., Mol Psychiatry
Park S et al., 2014, Catechol-O-methyltransferase Val158-Met polymorphism and a response of hyperactive-impulsive symptoms to methylphenidate: A replication study from South Korea., J Psychopharmacol
Yatsuga C et al., 2014, No association between catechol-O-methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children., Brain Dev
Contini V et al., 2012, No significant association between genetic variants in 7 candidate genes and response to methylphenidate treatment in adult patients with ADHD., J Clin Psychopharmacol
Green T et al., 2011, The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome., J Child Adolesc Psychopharmacol
Salatino-Oliveira A et al., 2011, Catechol-O-methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention-deficit/hyperactivity disorder., Biol Psychiatry
Cheon KA et al., 2008, Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder., Int Clin Psychopharmacol
Kereszturi E et al., 2008, Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children., Am J Med Genet B Neuropsychiatr Genet
Corvol JC et al., 2011, The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial., Ann Neurol
Najib, 2001, Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease., Clin Ther
Brooks et al., 2003, Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study., J. Neurol. Neurosurg. Psychiatr.
Chong et al., 2000, Entacapone., Ann Pharmacother
Holm et al., 1999, Entacapone. A review of its use in Parkinson's disease., Drugs
Poewe et al., 2002, Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)., Acta Neurol. Scand.
Duan L et al., 2020, Association of <i>COMT</i> Gene Polymorphisms with Response to Methadone Maintenance Treatment Among Chinese Opioid-Dependent Patients., Genet Test Mol Biomarkers
Aubrun F et al., 2018, Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study., Eur J Anaesthesiol
Matic M et al., 2017, Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement., Pharmacogenomics
Hronová K et al., 2016, Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome., Physiol Res
Elens L et al., 2016, Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation., Ther Drug Monit
De Gregori M et al., 2016, Human Genetic Variability Contributes to Postoperative Morphine Consumption., J Pain
Candiotti KA et al., 2014, Catechol-o-methyltransferase polymorphisms predict opioid consumption in postoperative pain., Anesth Analg
Matic M et al., 2014, Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype., Pharmacogenomics
Cargnin S et al., 2013, An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans., J Pain
De Gregori M et al., 2013, Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain., Eur J Clin Pharmacol
Landau R et al., 2013, The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia., Anesth Analg
Klepstad P et al., 2011, Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients., Pain
Lötsch J et al., 2009, Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers., Pharmacogenet Genomics
Scott LJ, 2016, Opicapone: A Review in Parkinson's Disease., Drugs
Tardy B et al., 2006, Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin., Blood
Choi HD et al., 2015, Association between catechol-O-methyltransferase (COMT) Val/Met genotype and smoking cessation treatment with nicotine: a meta-analysis., Pharmacogenomics
Sun H et al., 2012, Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy., J Neural Transm (Vienna)
Munafò MR et al., 2008, Association of COMT Val108/158Met genotype with smoking cessation., Pharmacogenet Genomics
Beuten J et al., 2006, Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations., Neuropsychopharmacology
David SP et al., 2002, No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation., Pharmacogenetics
Cargnin S et al., 2014, Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache., Eur J Clin Pharmacol
Benedetti F et al., 2009, The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting., Psychopharmacology (Berl)
de Jong C et al., 2017, Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman., Br J Clin Pharmacol
Drögemöller BI et al., 2017, Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer., JAMA Oncol
Thiesen S et al., 2017, TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity., Pharmacogenet Genomics
Hagleitner MM et al., 2014, Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts., PLoS One
Carleton BC et al., 2014, Genetic markers of cisplatin-induced hearing loss in children., Clin Pharmacol Ther
Lanvers-Kaminsky C et al., 2014, Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity., Clin Pharmacol Ther
Yang JJ et al., 2013, The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer., Clin Pharmacol Ther
Pussegoda K et al., 2013, Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children., Clin Pharmacol Ther
Ross CJ et al., 2009, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy., Nat Genet
Bosia M et al., 2015, COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine., Pharmacogenomics
Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
Zivković M et al., 2013, The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol., J Clin Psychopharmacol
Muriel J et al., 2019, Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients., Basic Clin Pharmacol Toxicol
Xu Q et al., 2016, Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population., Pharmacogenomics J
Saiz-Rodríguez M et al., 2019, Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects., Basic Clin Pharmacol Toxicol
Goudreau JL et al., 2002, Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease., Mov Disord
Woo JM et al., 2002, Catechol O-methyltransferase genetic polymorphism in panic disorder., Am J Psychiatry
Dauvilliers Y et al., 2002, Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil., Pharmacogenomics J
Alsobrook JP 2nd et al., 2002, Association between the COMT locus and obsessive-compulsive disorder in females but not males., Am J Med Genet
Ohara K et al., 1998, Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression., Neuroreport
Li T et al., 1997, Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder., Pharmacogenetics
Stein MB et al., 2005, COMT polymorphisms and anxiety-related personality traits., Neuropsychopharmacology
Enoch MA et al., 2003, Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism., Psychiatr Genet
Berrettini WH et al., 2007, Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence., Biol Psychiatry
Taranu A et al., 2017, The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings., Basic Clin Pharmacol Toxicol
Hopkins SC et al., 2013, Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder., Psychiatry Res
Narasimhan S et al., 2012, Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder., Psychiatry Res
Horowitz R et al., 2000, Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study., Am J Med Genet
Vandenbergh DJ et al., 1997, High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers., Am J Med Genet
Rakvåg TT et al., 2005, The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients., Pain
Zubieta JK et al., 2003, COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor., Science
Zhao QZ et al., 2012, Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study., Psychiatr Genet
Fijal BA et al., 2009, Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia., Pharmacogenomics J

ENTACAPONE COMT

Interaction Score: 15.46

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name entacapone, Comtan

Novel drug target Established target

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
21280081 11440283 12876237 12538800 10981253 10882160 11873938 10439935 9808337 11939936 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD
TOLCAPONE COMT

Interaction Score: 14.49

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Catechol O-methyltransferase inhibitor

PMIDs:
18046910 19503773 20502133 10882160 11873938 15697329 9808337 11752352 17063156 12538800 9917075

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD
OPICAPONE COMT

Interaction Score: 5.8

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

Interaction Info:

PMIDs:
27498199 16690967

Sources:
TTD
REMIFENTANIL COMT

Interaction Score: 5.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources:
PharmGKB
SUFENTANIL COMT

Interaction Score: 3.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources:
PharmGKB
OXYCODONE COMT

Interaction Score: 2.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources:
PharmGKB
MODAFINIL COMT

Interaction Score: 1.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12465073 12359690 11990384 11840516 9631418 9352569 15956988 12605099

Sources:
PharmGKB
MORPHINE COMT

Interaction Score: 1.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130 11054766 9259381 15927391 12595695

Sources:
PharmGKB
METHADONE COMT

Interaction Score: 0.97

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32407152 29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources:
PharmGKB
BENZTROPINE COMT

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
TRIHEXYPHENIDYL COMT

Interaction Score: 0.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VENLAFAXINE COMT

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28627776 23706899 22417933

Sources:
PharmGKB
BUPRENORPHINE COMT

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30549211

Sources:
PharmGKB
METHYLPHENIDATE COMT

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29230023 24763183 24035255 23131881 22149470 21550019 18703939 18214865

Sources:
PharmGKB
FLUVOXAMINE COMT

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20619611

Sources:
PharmGKB
SUMATRIPTAN COMT

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25096645

Sources:
PharmGKB
NICOTINE COMT

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26555332 22695756 18192898 16395295 11927842

Sources:
PharmGKB
FENTANYL COMT

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30549211 30281924

Sources:
PharmGKB
BUPROPION COMT

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16876132

Sources:
PharmGKB
PAROXETINE COMT

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18989660

Sources:
PharmGKB
DIACETYLMORPHINE COMT

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
QUETIAPINE COMT

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26282453

Sources:
PharmGKB
CISPLATIN COMT

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28560854 28448657 28445188 25551397 25141953 24642735 23820299 23588304 19898482

Sources:
PharmGKB
RISPERIDONE COMT

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22935916 19451915

Sources:
PharmGKB
SERTRALINE COMT

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
HALOPERIDOL COMT

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 23963056

Sources:
PharmGKB
NOREPINEPHRINE COMT

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METHYLDOPA COMT

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CLOZAPINE COMT

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25560469

Sources:
PharmGKB
LEVODOPA COMT

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LITHIUM COMT

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OLANZAPINE COMT

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000093010
- Version: 101_38
Alternate Names:

COMT Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P21964
- Version: 01-August-2011
Alternate Names:

1312 Entrez Gene Id

COMT_HUMAN Uniprot Id

ENSG00000093010 Ensembl Gene Id

Gene Info:

Target Main Class Enzymes

Target Subclass 2.1.1.6

Publications:
TdgClinicalTrial: P21964
- Version: January-2014
Alternate Names:

COMT Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:2.1.1.6

Publications:

PharmGKB: COMT

Version: 18-August-2020

Alternate Names:

PA117 PharmGKB ID

Gene Info:

Publications:

Benedetti F et al., 2010, Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine., Eur Psychiatry

Ross CJ et al., 2009, Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy., Nat Genet

Thiesen S et al., 2017, TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity., Pharmacogenet Genomics

ChemblInteractions: COMT
- Version: chembl_23
Alternate Names:

COMT GENE_SYMBOL

Catechol O-methyltransferase UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000093010
- Version: 31-May-2017
Alternate Names:

ENSG00000093010 Gene Symbol

COMT Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
TTD: Catechol-O-methyl-transferase
- Version: 2020.06.01
Alternate Names:

COMT TTD Gene Abbreviation

T76904 TTD Target ID

Gene Info:

Publications:

Trial Name	entacapone, Comtan
Novel drug target	Established target
Trial Name	entacapone/levodopa/carbidopa,Stalevo

1312	Entrez Gene Id
COMT_HUMAN	Uniprot Id
ENSG00000093010	Ensembl Gene Id

antagonist (inhibitory)
inhibitor (inhibitory)

COMT Gene Record

COMT 1312 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name entacapone, Comtan Novel drug target Established target Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs: 21280081 11440283 12876237 12538800 10981253 10882160 11873938 10439935 9808337 11939936 11752352

Sources: TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Catechol O-methyltransferase inhibitor

PMIDs: 18046910 19503773 20502133 10882160 11873938 15697329 9808337 11752352 17063156 12538800 9917075

Sources: TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality: antagonist (inhibitory) inhibitor (inhibitory)

Interaction Info:

PMIDs: 27498199 16690967

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12465073 12359690 11990384 11840516 9631418 9352569 15956988 12605099

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130 11054766 9259381 15927391 12595695

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 32407152 29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28627776 23706899 22417933

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30549211

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29230023 24763183 24035255 23131881 22149470 21550019 18703939 18214865

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20619611

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25096645

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26555332 22695756 18192898 16395295 11927842

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30549211 30281924

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name entacapone, Comtan

Novel drug target Established target

Trial Name entacapone/levodopa/carbidopa,Stalevo

PMIDs:
21280081 11440283 12876237 12538800 10981253 10882160 11873938 10439935 9808337 11939936 11752352

Sources:
TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Catechol O-methyltransferase inhibitor

PMIDs:
18046910 19503773 20502133 10882160 11873938 15697329 9808337 11752352 17063156 12538800 9917075

Sources:
TdgClinicalTrial ChemblInteractions TEND TTD

Interaction Types & Directionality:

antagonist (inhibitory)

inhibitor (inhibitory)

PMIDs:
27498199 16690967

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12465073 12359690 11990384 11840516 9631418 9352569 15956988 12605099

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130 11054766 9259381 15927391 12595695

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
32407152 29474345 28745577 28006928 27027462 26902643 25185591 25155931 23773341 23686330 23302985 21398039 19514130

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28627776 23706899 22417933

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30549211

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29230023 24763183 24035255 23131881 22149470 21550019 18703939 18214865

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20619611

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25096645

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26555332 22695756 18192898 16395295 11927842

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30549211 30281924

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16876132

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18989660

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26282453

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28560854 28448657 28445188 25551397 25141953 24642735 23820299 23588304 19898482

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22935916 19451915

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27023437 23963056

Sources:
PharmGKB